Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

Cosmetic surgeons are seeing a new wave of patients seeking treatment for "Ozempic face" - the sagging, hollow appearance ...

With the use of these medications to help with weight loss and diabetes comes many questions about the long-term impact on ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

GLP-1 drugs like Ozempic are transforming weight loss, but a new UVA study warns they're not improving a critical measure of ...

Aggressive social media marketing by influencers has fuelled a surge in over-the-counter use of the diabetes and obesity ...

With over 40% of Americans classified as obese, the need for effective long-term weight-loss solutions is greater than ever. Obesity can lead to serious health issues like diabetes, heart disease, ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

The Trump administration has pledged to curb rising obesity with school meal reforms and artificial dye bans, though the ...

A major new study has shown that a group of drugs called GLP-1 receptor agonists offer strong protection for both the kidneys ...

Though GLP-1 drugs drive major weight loss, researchers warn they may fall short in improving heart and lung fitness. Protecting muscle mass may be key to unlocking their full health potential. Widely ...